| abstract |
The present invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing them, as well as glutamate dysfunction such as schizophrenia or dementia and cognitive impairment It relates to its use as a medicament for treating and / or preventing neurological and psychiatric disorders associated with cognitive decline. R1, R2, R3, R4 and Q have the meanings indicated in the specification. I |